{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:31Z","timestamp":1786982191376,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Development Fund of the Affiliated Hospital of Xuzhou Medical University","award":["No. XYFY2021031."],"award-info":[{"award-number":["No. XYFY2021031."]}]},{"name":"Development Fund of the Affiliated Hospital of Xuzhou Medical University","award":["No. XYFY2021031."],"award-info":[{"award-number":["No. XYFY2021031."]}]},{"name":"Development Fund of the Affiliated Hospital of Xuzhou Medical University","award":["No. XYFY2021031."],"award-info":[{"award-number":["No. XYFY2021031."]}]},{"name":"Development Fund of the Affiliated Hospital of Xuzhou Medical University","award":["No. XYFY2021031."],"award-info":[{"award-number":["No. XYFY2021031."]}]},{"name":"Development Fund of the Affiliated Hospital of Xuzhou Medical University","award":["No. XYFY2021031."],"award-info":[{"award-number":["No. XYFY2021031."]}]},{"name":"Development Fund of the Affiliated Hospital of Xuzhou Medical University","award":["No. XYFY2021031."],"award-info":[{"award-number":["No. XYFY2021031."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03998-8","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T05:02:45Z","timestamp":1724994165000},"page":"159-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db\/db mice"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0421-369X","authenticated-orcid":false,"given":"Jun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7125-5689","authenticated-orcid":false,"given":"Xiaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9731-0323","authenticated-orcid":false,"given":"Wencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6799-526X","authenticated-orcid":false,"given":"Mengyuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1252-0738","authenticated-orcid":false,"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-5152","authenticated-orcid":false,"given":"Weiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"11","key":"3998_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","volume":"17","author":"M Oshima","year":"2021","unstructured":"M. Oshima, M. Shimizu, M. Yamanouchi et al. Trajectories of kidney function in diabetes: a clinicopathological update. Nat. Rev. Nephrol. 17(11), 740\u2013750 (2021). https:\/\/doi.org\/10.1038\/s41581-021-00462-y","journal-title":"Nat. Rev. Nephrol."},{"issue":"24","key":"3998_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"V. Perkovic, M.J. Jardine, B. Neal et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295\u20132306 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"3998_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"H.J.L. Heerspink, B.V. Stef\u00e1nsson, R. Correa-Rotter et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383(15), 1436\u20131446 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"3998_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/circulationaha.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"A.M. Shaman, S.C. Bain, G.L. Bakris et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145(8), 575\u2013585 (2022). https:\/\/doi.org\/10.1161\/circulationaha.121.055459","journal-title":"Circulation"},{"issue":"2","key":"3998_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14740338.2017.1268598","volume":"16","author":"D Raccah","year":"2017","unstructured":"D. Raccah, Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues. Expert Opin. Drug Safety 16(2), 227\u2013236 (2017). https:\/\/doi.org\/10.1080\/14740338.2017.1268598","journal-title":"Expert Opin. Drug Safety"},{"issue":"3","key":"3998_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"K. Bettge, M. Kahle, M.S. Abd El Aziz, J.J. Meier, M.A. Nauck, Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes. Metab. 19(3), 336\u2013347 (2017). https:\/\/doi.org\/10.1111\/dom.12824","journal-title":"Diabetes Obes. Metab."},{"issue":"49","key":"3998_CR7","doi-asserted-by":"publisher","first-page":"35581","DOI":"10.1074\/jbc.M113.512046","volume":"288","author":"VA Gault","year":"2013","unstructured":"V.A. Gault, V.K. Bhat, N. Irwin, P.R. Flatt, A novel glucagon-like peptide-1 (GLP-1)\/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J. Biol. Chem. 288(49), 35581\u201335591 (2013). https:\/\/doi.org\/10.1074\/jbc.M113.512046","journal-title":"J. Biol. Chem."},{"issue":"12","key":"3998_CR8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","volume":"18","author":"SJ Henderson","year":"2016","unstructured":"S.J. Henderson, A. Konkar, D.C. Hornigold et al. Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 18(12), 1176\u20131190 (2016). https:\/\/doi.org\/10.1111\/dom.12735","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"3998_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2174\/0929866525666181120090857","volume":"25","author":"A Singh","year":"2018","unstructured":"A. Singh, V. Srivastava, Multi-functional chimeric peptides: the more the merrier. Protein Pept. Lett. 25(12), 1090\u20131100 (2018). https:\/\/doi.org\/10.2174\/0929866525666181120090857","journal-title":"Protein Pept. Lett."},{"issue":"10","key":"3998_CR10","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/j.bmc.2017.10.047","volume":"26","author":"PJ Knerr","year":"2018","unstructured":"P.J. Knerr, B. Finan, V. Gelfanov, D. Perez-Tilve, M.H. Tsch\u00f6p, R.D. DiMarchi, Optimization of peptide-based polyagonists for treatment of diabetes and obesity. Bioorg. Med. Chem. 26(10), 2873\u20132881 (2018). https:\/\/doi.org\/10.1016\/j.bmc.2017.10.047","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"3998_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2016.06.021","volume":"24","author":"MH Tsch\u00f6p","year":"2016","unstructured":"M.H. Tsch\u00f6p, B. Finan, C. Clemmensen et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 24(1), 51\u201362 (2016). https:\/\/doi.org\/10.1016\/j.cmet.2016.06.021","journal-title":"Cell Metab."},{"issue":"3","key":"3998_CR12","doi-asserted-by":"publisher","first-page":"E418-E426","DOI":"10.1210\/jc.2013-3644","volume":"99","author":"MB Christensen","year":"2014","unstructured":"M.B. Christensen, S. Calanna, J.J. Holst, T. Vilsb\u00f8ll, F.K. Knop, Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 99(3), E418-E426 (2014). https:\/\/doi.org\/10.1210\/jc.2013-3644","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"3998_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrendo.2010.187","volume":"6","author":"KM Habegger","year":"2010","unstructured":"K.M. Habegger, K.M. Heppner, N. Geary, T.J. Bartness, R. DiMarchi, M.H. Tsch\u00f6p, The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6(12), 689\u2013697 (2010). https:\/\/doi.org\/10.1038\/nrendo.2010.187","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"3998_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s005350050184","volume":"33","author":"E Mochiki","year":"1998","unstructured":"E. Mochiki, H. Suzuki, S. Takenoshita et al. Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J. Gastroenterol. 33(6), 835\u2013841 (1998). https:\/\/doi.org\/10.1007\/s005350050184","journal-title":"J. Gastroenterol."},{"key":"3998_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.peptides.2016.12.012","volume":"88","author":"G Song","year":"2017","unstructured":"G. Song, G. Pacini, B. Ahr\u00e9n, D.Z. D\u2019Argenio, Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice. Peptides 88, 74\u201379 (2017). https:\/\/doi.org\/10.1016\/j.peptides.2016.12.012","journal-title":"Peptides"},{"issue":"9","key":"3998_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/s2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"N. Inagaki, M. Takeuchi, T. Oura, T. Imaoka, Y. Seino, Efficacy and safety of Tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10(9), 623\u2013633 (2022). https:\/\/doi.org\/10.1016\/s2213-8587(22)00188-7","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"3998_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"A.M. Jastreboff, L.J. Aronne, N.N. Ahmad et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387(3), 205\u2013216 (2022). https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N. Engl. J. Med."},{"issue":"10366","key":"3998_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/s0140-6736(22)02033-5","volume":"400","author":"S Urva","year":"2022","unstructured":"S. Urva, T. Coskun, M.T. Loh et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 400(10366), 1869\u20131881 (2022). https:\/\/doi.org\/10.1016\/s0140-6736(22)02033-5","journal-title":"Lancet"},{"issue":"9","key":"3998_CR19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"T. Coskun, S. Urva, W.C. Roell et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 34(9), 1234\u20131247.e9 (2022). https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013","journal-title":"Cell Metab."},{"issue":"10397","key":"3998_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators, Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397), 203\u2013234 (2023). https:\/\/doi.org\/10.1016\/s0140-6736(23)01301-6","journal-title":"Lancet"},{"issue":"1-2","key":"3998_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejps.2006.01.003","volume":"28","author":"DK Arulmozhi","year":"2006","unstructured":"D.K. Arulmozhi, B. Portha, GLP-1 based therapy for type 2 diabetes. Eur. J. Pharmaceut. Sci. 28(1-2), 96\u2013108 (2006). https:\/\/doi.org\/10.1016\/j.ejps.2006.01.003","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"3998_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnins.2015.00092","volume":"9","author":"KM Heppner","year":"2015","unstructured":"K.M. Heppner, D. Perez-Tilve, GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front. Neurosci. 9, 92 (2015). https:\/\/doi.org\/10.3389\/fnins.2015.00092","journal-title":"Front. Neurosci."},{"issue":"10","key":"3998_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/dme.12299","volume":"30","author":"GA Hitman","year":"2013","unstructured":"G.A. Hitman, R.D. Leslie, R.I. Holt, GLP-1-based diabetes therapies; trial by media. Diabetic Med. 30(10), 1147 (2013). https:\/\/doi.org\/10.1111\/dme.12299","journal-title":"Diabetic Med."},{"issue":"11","key":"3998_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/s2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"H.J.L. Heerspink, N. Sattar, I. Pavo et al. Effects of Tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10(11), 774\u2013785 (2022). https:\/\/doi.org\/10.1016\/s2213-8587(22)00243-1","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3998_CR25","doi-asserted-by":"publisher","first-page":"118339","DOI":"10.1016\/j.lfs.2020.118339","volume":"260","author":"J Cui","year":"2020","unstructured":"J. Cui, A. Shang, W. Wang, W. Chen, Rational design of a GLP-1\/GIP\/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals. Life Sci. 260, 118339 (2020). https:\/\/doi.org\/10.1016\/j.lfs.2020.118339","journal-title":"Life Sci."},{"issue":"10","key":"3998_CR26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/ijo.2012.227","volume":"37","author":"JA Parker","year":"2013","unstructured":"J.A. Parker, K.A. McCullough, B.C. Field et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int. J. Obes. 37(10), 1391\u20131398 (2013). https:\/\/doi.org\/10.1038\/ijo.2012.227","journal-title":"Int. J. Obes."},{"issue":"3","key":"3998_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1517\/14728222.9.3.593","volume":"9","author":"KW Sloop","year":"2005","unstructured":"K.W. Sloop, M.D. Michael, J.S. Moyers, Glucagon as a target for the treatment of Type 2 diabetes. Expert Opin. Ther. Targets 9(3), 593\u2013600 (2005). https:\/\/doi.org\/10.1517\/14728222.9.3.593","journal-title":"Expert Opin. Ther. Targets"},{"key":"3998_CR28","doi-asserted-by":"publisher","first-page":"8871677","DOI":"10.1155\/2023\/8871677","volume":"2023","author":"YZ Han","year":"2023","unstructured":"Y.Z. Han, H.J. Zheng, B.X. Du et al. Role of gut microbiota, immune imbalance, and allostatic load in the occurrence and development of diabetic kidney disease. J. Diabetes Res. 2023, 8871677 (2023). https:\/\/doi.org\/10.1155\/2023\/8871677","journal-title":"J. Diabetes Res."},{"issue":"3","key":"3998_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1530\/joe-18-0137","volume":"238","author":"YH Xu","year":"2018","unstructured":"Y.H. Xu, C.L. Gao, H.L. Guo et al. Sodium butyrate supplementation ameliorates diabetic inflammation in db\/db mice. J. Endocrinol. 238(3), 231\u2013244 (2018). https:\/\/doi.org\/10.1530\/joe-18-0137","journal-title":"J. Endocrinol."},{"issue":"1","key":"3998_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/joe-16-0322","volume":"232","author":"W Dong","year":"2017","unstructured":"W. Dong, Y. Jia, X. Liu et al. Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC. J. Endocrinol. 232(1), 71\u201383 (2017). https:\/\/doi.org\/10.1530\/joe-16-0322","journal-title":"J. Endocrinol."},{"key":"3998_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.fct.2014.08.010","volume":"73","author":"S Khan","year":"2014","unstructured":"S. Khan, G. Jena, Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-\u03b21-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem. Toxicol. 73, 127\u2013139 (2014). https:\/\/doi.org\/10.1016\/j.fct.2014.08.010","journal-title":"Food Chem. Toxicol."},{"issue":"7","key":"3998_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00592-020-01657-8","volume":"58","author":"J Charpentier","year":"2021","unstructured":"J. Charpentier, F. Briand, B. Lelouvier et al. Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion. Acta Diabetol. 58(7), 881\u2013897 (2021). https:\/\/doi.org\/10.1007\/s00592-020-01657-8","journal-title":"Acta Diabetol."},{"key":"3998_CR33","doi-asserted-by":"publisher","first-page":"118457","DOI":"10.1016\/j.lfs.2020.118457","volume":"261","author":"Q Liu","year":"2020","unstructured":"Q. Liu, B.Y. Cai, L.X. Zhu et al. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db\/db mice. Life Sci. 261, 118457 (2020). https:\/\/doi.org\/10.1016\/j.lfs.2020.118457","journal-title":"Life Sci."},{"issue":"6","key":"3998_CR34","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","volume":"44","author":"R Nahra","year":"2021","unstructured":"R. Nahra, T. Wang, K.M. Gadde et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care 44(6), 1433\u20131442 (2021). https:\/\/doi.org\/10.2337\/dc20-2151","journal-title":"Diabetes Care"},{"issue":"2","key":"3998_CR35","doi-asserted-by":"publisher","first-page":"e12432","DOI":"10.1111\/cob.12432","volume":"11","author":"M Alba","year":"2021","unstructured":"M. Alba, J. Yee, M.E. Frustaci, M.N. Samtani, P. Fleck, Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clin. Obes. 11(2), e12432 (2021). https:\/\/doi.org\/10.1111\/cob.12432","journal-title":"Clin. Obes."},{"issue":"10401","key":"3998_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/s0140-6736(23)01053-x","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"J. Rosenstock, J. Frias, A.M. Jastreboff et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401), 529\u2013544 (2023). https:\/\/doi.org\/10.1016\/s0140-6736(23)01053-x","journal-title":"Lancet"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03998-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03998-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03998-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T07:53:22Z","timestamp":1737014002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03998-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3998"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03998-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}